Cutaneous immune-related adverse events associated with improved progression-free survival in non-small cell lung cancer
Skin reactions in lung cancer patients may signal longer life with certain treatments
This meta-analysis evaluated patients with non-small cell lung cancer receiving anti-PD-1, PD-L1, or chemotherapy. The analysis found that c…
A large review found that specific skin reactions linked to cancer drugs are connected to longer survival times for some lung cancer patient…
Meta-analysis of neoadjuvant anti-PD-1/PD-L1 plus chemotherapy in resectable NSCLC reports resection and response rates
Combining checkpoint inhibitors with chemotherapy helps more lung cancer patients get surgery safely
This meta-analysis synthesized outcomes from 1,885 patients with potentially resectable non-small cell lung cancer who received neoadjuvant …
A review of 1,885 patients found that adding immune therapy to standard chemo before surgery helped many get clean operations. About one in …
High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
High Mutation Counts May Predict Better Cancer Survival Outcomes
This systematic review and meta-analysis evaluated 5278 patients with solid tumours treated with immune checkpoint inhibitors or chemotherap…
High mutation counts in tumors may help predict who will survive longer when taking powerful immune-boosting cancer drugs
Anti-PD-1 plus chemoradiotherapy improved event-free survival in MS1 subtype nasopharyngeal carcinoma patients compared with chemoradiotherapy alone
New Test Picks Who Wins From Cancer Drug
This review analyzed pooled data from two Phase III randomized clinical trials involving 407 patients with locoregionally advanced nasophary…
A new test identifies which nasopharyngeal cancer patients will survive longer when adding immunotherapy to standard radiation and chemother…